Characteristic | First cohort (n = 24) |
---|---|
Age, years | 68 (55–72) |
Female, n (%) | 20 (83) |
Disease duration, months | 36 (6–153) |
Stage I/II/III/IV, n | 9/8/2/5 |
Class 1/2/3/4, n | 5/14/4/0 |
RF-positive, n (%) | 19 (79) |
ACPA-positive, n (%) | 20 (87)a |
Methotrexate use, n (%) | 13 (54) |
Biologic use, n (%) | 8 (33) |
DAS28-ESR | 4.6 (3.6–5.8)a |